Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
222 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05116579 | Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) | unknown | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT05613738 | 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | N/A | 9 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05579184 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2(LUCIDA_2) | unknown | Phase 2 | 20 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT03700099 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05558956 | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | unknown | Early Phase 1 | 100 | BAMF HealthOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
| NCT03381326 | CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.(IRSTB030) | unknown | — | 104 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05823402 | Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)(SPECTacular) | unknown | N/A | 30 | BAMF HealthOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05533203 | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) | unknown | Phase 1 | 24 | Shanghai Humantech Biotechnology Co. LtdINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03601143 | Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients(PEARL) | unknown | — | 120 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05327621 | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05262608 | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation(PROspect) | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05188911 | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | unknown | — | 30 | Fudan UniversityOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03305224 | The Combination Therapy With Ra-223 and Enzalutamide(CORE-OCU) | unknown | Phase 2 | 10 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04567875 | Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma(Apa-CARDIO1) | unknown | — | 54 | Ospedale Andrea Tortora di PaganiNETWORK | 1 | Sep 29, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03934164 | Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO(MAESTRO) | unknown | — | 600 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04225910 | Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer | unknown | Early Phase 1 | 20 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT04188587 | 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03960788 | Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer | unknown | Early Phase 1 | 50 | University of CincinnatiOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT03696186 | Selective Treatment According to Molecular Subtype of Prostate Cancer(STAMP) | unknown | Phase 2 | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03177551 | Predictive Nomogram of CRPC(CRPC-PN) | unknown | — | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 1, 2018 | clinicaltrials |
| NCT03439397 | RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients | unknown | N/A | 496 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Mar 1, 2018 | clinicaltrials |
| NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03356912 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | unknown | Phase 2 | 220 | Consorzio OncotechOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT03356444 | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 140 | West China HospitalOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02502994 | Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC | unknown | Phase 1 | 12 | Norio NonomuraOTHER | 1 | Jul 20, 2015 | clinicaltrials |
| NCT00684970 | Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)(TLH-202) | unknown | Phase 2 | 100 | Tiltan Pharma Ltd.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT01487902 | The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | unknown | Phase 2 | 90 | Asan Medical CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2024source: clinicaltrials